国信证券陈益凌：关注双抗和ADC领域的创新药投资机会

Core Viewpoint - The focus is on the potential of dual antibodies and ADC (antibody-drug conjugates) in the oncology sector, highlighting their broad therapeutic applications and significant overseas commercial potential [1] Group 1: Oncology Sector Insights - The oncology field, particularly dual antibodies and ADC products, is seen as having extensive potential due to the complexity of solid tumor indications [1] - There is a notable overseas commercial potential for these innovative drug segments [1] Group 2: CXO and R&D Services - The recovery in domestic and international innovative drug R&D and financing is expected to sustain a high level of prosperity in the CXO (Contract Research Organization) sector, especially in the ADC and broader XDC (various conjugated drugs) fields [1] Group 3: Investment Strategy and Market Outlook - The development and clinical trials of innovative drugs typically require several years for approval and commercialization, indicating a gradual rather than immediate market performance [1] - The innovative drug sector is anticipated to experience more frequent and significant milestone events by 2026, suggesting that both short-term trading opportunities and long-term investment strategies could perform well in this sector [1]